BioCentury on BioBusiness,
Tools & Techniques
DevCo's lexipafant renaissance
Monday, March 27, 2000
Nearly a year to the day that British Biotech plc announced that it was
dropping Zacutex lexipafant as a potential treatment for acute pancreatitis, DevCo Pharmaceuticals Ltd. announced plans to resurrect the platelet activating factor
antagonist for the prophylaxis of neurological and renal complications in patients
undergoing cardiac surgery.
"There is evidence that a variety of inflammatory mediators,
including platelet-activating factor (PAF), may contribute to neuronal injury," said
Chris Jordan, DevCo portfolio management director. Armed with this information, DevCo
(Guildford, U.K.), a virtual biotech company with a neuroscience focus, is
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]